Nasdaq listed VectivBio Holding, a clinical-stage biopharmaceutical company, has announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a price of US$5.25 per share to raise…
Nasdaq listed VectivBio Holding, a clinical-stage biopharmaceutical company, has announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a price of US$5.25 per share to raise…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference